View Future GrowthAvalyn Pharma 과거 순이익 실적과거 기준 점검 0/6Avalyn Pharma의 수입은 연평균 -61.7%의 비율로 감소해 온 반면, Pharmaceuticals 산업의 수입은 연간 9.4% 증가했습니다.핵심 정보-61.69%순이익 성장률51.25%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률n/a자기자본이익률-87.58%순이익률n/a최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates속보 • Jun 18Avalyn Pharma Stock in Focus as Phase 2b MIST Trial Hits Patient Enrollment Goal EarlyAvalyn Pharma has completed target enrollment of 375 patients in its Phase 2b MIST trial evaluating AP01, an inhaled form of pirfenidone, for progressive pulmonary fibrosis (PPF). The MIST trial reached full enrollment ahead of schedule, indicating strong demand from patients and clinicians for additional treatment options in PPF. Avalyn expects to report topline 12‑month clinical results from the MIST trial in the second half of 2027. Completion of enrollment in this key Phase 2b study marks an important clinical milestone for Avalyn Pharma, as it moves AP01 further along the development path for patients with progressive pulmonary fibrosis. Investors will likely focus on the eventual MIST readout timing and any interim updates, while also considering the usual clinical, regulatory, and funding risks that apply to late-stage drug development.공시 • Jun 17Avalyn Pharma Inc. Completes Target Enrollment In Phase 2b MIST Trial Of AP01 For Patients With Progressive Pulmonary FibrosisAvalyn Pharma Inc. completed target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF). Additional patients currently in screening remain eligible for randomization and may be enrolled in the trial over the next several weeks. MIST is a global, randomized, double-blinded, placebo-controlled Phase 2b clinical trial evaluating the safety and efficacy of two doses of AP01 in patients with PPF. MIST was designed to enroll 375 patients with PPF, randomized 2:1:2 into three cohorts: AP01 100 mg twice-daily, AP01 50 mg twice-daily, and placebo. The primary endpoint is the change from baseline in lung function, as measured by forced vital capacity (FVC), at 52 weeks. Based on data from the ATLAS Phase 1b trial and ongoing open-label extension study, AP01’s tolerability profile may enable patients to remain on treatment longer. AP01 is an optimized formulation of pirfenidone administered using the PARI eRapid Nebulizer System. AP01 is currently in clinical development for the treatment of progressive pulmonary fibrosis. In the ATLAS Phase 1b study comparing 100 mg twice-daily and 50 mg once-daily doses of AP01, results showed low rates of side effects, including gastrointestinal toxicities and liver enzyme elevations, and suggested a trend toward stability in lung function at the higher dose. AP01 is currently being evaluated in the MIST Phase 2b trial in patients with PPF.속보 • Jun 04Avalyn Pharma Advances Mid-Stage Lung Trials With US$345 Million IPO FundingAvalyn reported first quarter 2026 results and highlighted progress across its inhaled fibrosis programs. The MIST Phase 2b trial of lead candidate AP01 in progressive pulmonary fibrosis is expected to complete enrollment in mid-2026, supported by favorable long-term clinical data. Enrollment is ongoing in the AURA Phase 2 trial of AP02 in idiopathic pulmonary fibrosis, with topline data planned by the end of 2027, and the company recently completed an upsized IPO raising about US$345.0 million to fund operations through 2029. The key takeaway is that Avalyn is now well funded for several years while it advances two mid-stage clinical trials targeting serious lung diseases. Investors should keep in mind that clinical and regulatory outcomes for AP01 and AP02 remain central risks, since Avalyn’s current value is closely tied to trial progress and eventual approval prospects.공시 • May 01Avalyn Pharma Inc. has completed an IPO in the amount of $300.000006 million.Avalyn Pharma Inc. has completed an IPO in the amount of $300.000006 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 16,666,667 Price\Range: $18 Discount Per Security: $1.26 Transaction Features: Sponsor Backed Offering매출 및 비용 세부 내역Avalyn Pharma가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqGS:AVLN 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 260-95168431 Dec 250-851577양질의 수익: AVLN 은(는) 현재 수익성이 없습니다.이익 마진 증가: AVLN는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: AVLN은 상장된 지 3년이 되지 않아 지난 5년간 전년 대비 수익 증가율이 긍정적인지 확인할 수 없습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 AVLN의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: AVLN은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-4.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: AVLN는 현재 수익성이 없으므로 자본 수익률이 음수(-87.58%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/01 21:41종가2026/07/01 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Avalyn Pharma Inc.는 4명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gavin Clark-GartnerEvercore ISISeamus FernandezGuggenheim Securities, LLCRoger SongJefferies LLC1명의 분석가 더 보기
속보 • Jun 18Avalyn Pharma Stock in Focus as Phase 2b MIST Trial Hits Patient Enrollment Goal EarlyAvalyn Pharma has completed target enrollment of 375 patients in its Phase 2b MIST trial evaluating AP01, an inhaled form of pirfenidone, for progressive pulmonary fibrosis (PPF). The MIST trial reached full enrollment ahead of schedule, indicating strong demand from patients and clinicians for additional treatment options in PPF. Avalyn expects to report topline 12‑month clinical results from the MIST trial in the second half of 2027. Completion of enrollment in this key Phase 2b study marks an important clinical milestone for Avalyn Pharma, as it moves AP01 further along the development path for patients with progressive pulmonary fibrosis. Investors will likely focus on the eventual MIST readout timing and any interim updates, while also considering the usual clinical, regulatory, and funding risks that apply to late-stage drug development.
공시 • Jun 17Avalyn Pharma Inc. Completes Target Enrollment In Phase 2b MIST Trial Of AP01 For Patients With Progressive Pulmonary FibrosisAvalyn Pharma Inc. completed target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF). Additional patients currently in screening remain eligible for randomization and may be enrolled in the trial over the next several weeks. MIST is a global, randomized, double-blinded, placebo-controlled Phase 2b clinical trial evaluating the safety and efficacy of two doses of AP01 in patients with PPF. MIST was designed to enroll 375 patients with PPF, randomized 2:1:2 into three cohorts: AP01 100 mg twice-daily, AP01 50 mg twice-daily, and placebo. The primary endpoint is the change from baseline in lung function, as measured by forced vital capacity (FVC), at 52 weeks. Based on data from the ATLAS Phase 1b trial and ongoing open-label extension study, AP01’s tolerability profile may enable patients to remain on treatment longer. AP01 is an optimized formulation of pirfenidone administered using the PARI eRapid Nebulizer System. AP01 is currently in clinical development for the treatment of progressive pulmonary fibrosis. In the ATLAS Phase 1b study comparing 100 mg twice-daily and 50 mg once-daily doses of AP01, results showed low rates of side effects, including gastrointestinal toxicities and liver enzyme elevations, and suggested a trend toward stability in lung function at the higher dose. AP01 is currently being evaluated in the MIST Phase 2b trial in patients with PPF.
속보 • Jun 04Avalyn Pharma Advances Mid-Stage Lung Trials With US$345 Million IPO FundingAvalyn reported first quarter 2026 results and highlighted progress across its inhaled fibrosis programs. The MIST Phase 2b trial of lead candidate AP01 in progressive pulmonary fibrosis is expected to complete enrollment in mid-2026, supported by favorable long-term clinical data. Enrollment is ongoing in the AURA Phase 2 trial of AP02 in idiopathic pulmonary fibrosis, with topline data planned by the end of 2027, and the company recently completed an upsized IPO raising about US$345.0 million to fund operations through 2029. The key takeaway is that Avalyn is now well funded for several years while it advances two mid-stage clinical trials targeting serious lung diseases. Investors should keep in mind that clinical and regulatory outcomes for AP01 and AP02 remain central risks, since Avalyn’s current value is closely tied to trial progress and eventual approval prospects.
공시 • May 01Avalyn Pharma Inc. has completed an IPO in the amount of $300.000006 million.Avalyn Pharma Inc. has completed an IPO in the amount of $300.000006 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 16,666,667 Price\Range: $18 Discount Per Security: $1.26 Transaction Features: Sponsor Backed Offering